Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 241 AL 255

Alzheimer's disease: a review of recent developments

Salawu FK, Umar JT, Olokoba AB.

Ann Afr Med. 2011 Apr-Jun;10(2):73-9. doi: 10.4103/1596-3519.82057.

Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial

Wharton W, Baker LD, Gleason CE, Dowling M, Barnet JH, Johnson S, Carlsson C, Craft S, Asthana S.

J Alzheimers Dis. 2011;26(3):495-505. doi: 10.3233/JAD-2011-110341.

A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease

Stein MS, Scherer SC, Ladd KS, Harrison LC.

J Alzheimers Dis. 2011;26(3):477-84. doi: 10.3233/JAD-2011-110149.

Changes in cerebral glucose metabolism in patients with mild-to-moderate Alzheimer's disease: a pilot study with the Chinese herbal medicine fuzhisan

Bi M, Tong S, Zhang Z, Ma Q, Zhang S, Luo Z, Zhang Y, Li X, Wang D.

Neurosci Lett. 2011 Aug 21;501(1):35-40. doi: 10.1016/j.neulet.2011.06.036. Epub 2011 Jun 29.

Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity

Neugroschl J, Wang S.

Mt Sinai J Med. 2011 Jul-Aug;78(4):596-612. doi: 10.1002/msj.20279.

[An elderly patient with senile dementia showing acquired hemophilia A]

Yano H, Tsunoda M, Onishi T, Mizuno S, Koibuchi H, Kigawa Y, Suzuki T, Nakano H, Oba K.

Nihon Ronen Igakkai Zasshi. 2011;48(2):185-9. doi: 10.3143/geriatrics.48.185.

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS.

Neurology. 2011 Aug 9;77(6):556-63. doi: 10.1212/WNL.0b013e318228bf11. Epub 2011 Jul 27.

Nanomedicine in the European Commission policy for nanotechnology

Gabellieri C, Frima H.

Nanomedicine. 2011 Oct;7(5):519-20. doi: 10.1016/j.nano.2011.07.003. Epub 2011 Jul 28.

Behavioural and cellular effects of exogenous amyloid-β peptides in rodents

Chambon C, Wegener N, Gravius A, Danysz W.

Behav Brain Res. 2011 Dec 1;225(2):623-41. doi: 10.1016/j.bbr.2011.08.024. Epub 2011 Aug 22.

Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study

Kavanagh S, Van Baelen B, Schäuble B.

J Alzheimers Dis. 2011;27(3):521-30. doi: 10.3233/JAD-2011-110417.

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM; ELND005-AD201 Investigators.

Neurology. 2011 Sep 27;77(13):1253-62. doi: 10.1212/WNL.0b013e3182309fa5. Epub 2011 Sep 14.

MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia

Ashford JW, Adamson M, Beale T, La D, Hernandez B, Noda A, Rosen A, O'Hara R, Fairchild JK, Spielman D, Yesavage JA.

J Alzheimers Dis. 2011;26 Suppl 3(0 3):331-6. doi: 10.3233/JAD-2011-0021.

Experimental research on nitric oxide and the therapy of Alzheimer disease: a challenging bridge

Siciliano R, Barone E, Calabrese V, Rispoli V, Butterfield DA, Mancuso C.

CNS Neurol Disord Drug Targets. 2011 Nov;10(7):766-76. doi: 10.2174/187152711798072356.

[Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia]

Gavrilova SI, Kalyn IaB, Kolykhalov IV, Roshchina IF, Selezneva ND.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(9):16-22.

Charting the path for early diagnosis and prevention of Alzheimer's disease

Quiroz YT, Lopera F, Budson AE.

Expert Rev Neurother. 2011 Dec;11(12):1665-7. doi: 10.1586/ern.11.162.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias